Aura Biosciences, Inc.
AURA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$6.18
KIRA · Stoqly’s AI analyst, in plain words
- Aura Biosciences, Inc. had $6.6M of revenue in fiscal 2025, down 29.7% on the year before.
- Its operating margin was −1,701.0%, down 681.6 pts: of every 100 in sales, about −1,701 is left after running the business.
- Aura Biosciences, Inc. lost $106M in fiscal 2025.
- Free cash flow was −$85.2M in fiscal 2025, −1,284.7% of revenue.
Market cap
$586M
P/E
—
Revenue
$6.6M
Net income
−$106M
Free cash flow
−$85.2M
Operating margin
−1,701.0%
Aura Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−29.7%
No. Sales fell 29.7% last year.
Does it make a profit?
−1,601.4%
No. It lost money last year.
Does profit turn into cash?
−1,284.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Aura Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Aura Biosciences, Inc.
- CIK
- 0001501796
Aura Biosciences, Inc. · AURA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $1.9M | $8.6M | $9.4M | $6.6M |
| Revenue growth | — | 14,238.5% | 360.7% | 9.8% | −29.7% |
| Net interest income | $0.0M | $1.9M | $8.6M | $9.4M | $6.6M |
| Operating margin | −271,153.8% | −3,234.7% | −989.6% | −1,019.4% | −1,701.0% |
| Net income | −$35.3M | −$58.8M | −$76.4M | −$86.9M | −$106M |
| Net margin | −271,161.5% | −3,152.5% | −889.7% | −921.8% | −1,601.4% |
| Diluted EPS | −$8.95 | −$1.96 | −$1.93 | −$1.75 | −$1.76 |
| Cash | |||||
| Cash from operations | −$32.4M | −$54.6M | −$63.8M | −$79.8M | −$84.7M |
| Capital expenditure | $2.1M | $1.1M | $0.7M | $1.3M | $0.4M |
| Free cash flow | −$34.5M | −$55.7M | −$64.6M | −$81.1M | −$85.2M |
| FCF margin | −265,653.8% | −2,987.9% | −751.7% | −859.7% | −1,284.7% |
| Share count change | 1,305.2% | 480.2% | 32.3% | 25.3% | 21.5% |
| Debt and strength | |||||
| Cash and short-term investments | $149M | $122M | $41.1M | $31.7M | $59.5M |
| Shareholders' equity | $152M | $196M | $226M | $152M | $137M |
| Current ratio | 20.9x | 18.8x | 18.8x | 10.8x | 8.1x |
| Returns and quality | |||||
| Return on equity | −161.7% | −33.8% | −36.3% | −46.0% | −73.5% |
| Return on tangible equity | −23.1% | −30.0% | −33.8% | −57.2% | −77.6% |
| Piotroski F-score | 4 | 2 | 2 | 2 | 1 |
| Altman Z'' | 22.1 | 7.8 | 7.8 | 0.2 | −4.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$40.0M
7 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Aura Biosciences, Inc. · AURA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.18 a share, the company is worth $586M.
Source: SEC EDGAR XBRL filings (CIK 0001501796). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.